Should we screen Eastern Mediterranean sickle beta-thalassemia patients for inherited thrombophilia? [7]

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 3, 2005, Pages 599-600

  Otrock, Z K ^a   Mahfouz, R A R ^a   Taher, Ali T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; WARFARIN; BLOOD CLOTTING FACTOR 5; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

BETA THALASSEMIA; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR; SCREENING; SICKLE CELL ANEMIA; THALASSEMIA MAJOR; THROMBOPHILIA; FAMILY HEALTH; GENETICS; MASS SCREENING; SOUTHERN EUROPE;

ANEMIA, SICKLE CELL; BETA-THALASSEMIA; FACTOR V; FAMILY HEALTH; HUMANS; MASS SCREENING; MEDITERRANEAN REGION; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); THROMBOPHILIA;

EID: 23944506662     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01148.x     Document Type: Letter

References (8)

1. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003; 115: 721-8.
2. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99: 36-43.
3. Rosen SD, Sturk A. Activated protein C resistance-a major risk factor for thrombosis. Eur J Clin Chem Clin Biochem 1997; 35: 501-16.
4. Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromobembolism. Blood 1995; 85: 607-14.
5. Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 2000; 65: 45-9.
6. Taher A, Khalil I, Shamseddine A, El-Ahdab F, Bazarbachi A. High prevalence of factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation? Thromb Haemost 2001; 86: 723-4.
7. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH, Shehan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Andria G. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
8. Almawi WY, Finan RR, Tamim H, Daccahe JL, Irani-Hakime N. Differences in the frequency of the C677T mutation in the methylene-tetrahydrofolate reductase (MTHFR) gene among the Lebanese population. Am J Med 2004; 76: 85-7.